The incidence of anti-mGluR5 encephalitis in clinical settings is remarkably low, mainly manifesting cognitive deficit, mental disorders, epilepsy, disturbance of consciousness, and sleep disorders. This evidence concerns the gene GRM5 and epilepsy.